Business Description
Gilead Sciences Inc
NAICS : 325412
SIC : 2834
ISIN : US3755581036
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.19 | |||||
Equity-to-Asset | 0.31 | |||||
Debt-to-Equity | 1.44 | |||||
Debt-to-EBITDA | 5.27 | |||||
Interest Coverage | 6.64 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.16 | |||||
Beneish M-Score | -2.73 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.3 | |||||
3-Year EBITDA Growth Rate | 36.6 | |||||
3-Year EPS without NRI Growth Rate | 24.5 | |||||
3-Year FCF Growth Rate | -0.3 | |||||
3-Year Book Growth Rate | 8.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 5.39 | |||||
Future 3-5Y Total Revenue Growth Rate | 2.4 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
12-1 Month Momentum % | -4.26 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.08 | |||||
Quick Ratio | 0.94 | |||||
Cash Ratio | 0.36 | |||||
Days Inventory | 93.45 | |||||
Days Sales Outstanding | 59.86 | |||||
Days Payable | 33.01 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Payout Ratio | 0.85 | |||||
3-Year Dividend Growth Rate | 3.3 | |||||
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | 5.89 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 75.78 | |||||
Operating Margin % | 23.43 | |||||
Net Margin % | 1.76 | |||||
FCF Margin % | 28.78 | |||||
ROE % | 2.31 | |||||
ROA % | 0.79 | |||||
ROIC % | 5.25 | |||||
ROC (Joel Greenblatt) % | 37.48 | |||||
ROCE % | 4.18 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 183.22 | |||||
Forward PE Ratio | 17.19 | |||||
PE Ratio without NRI | 18.64 | |||||
Shiller PE Ratio | 10.81 | |||||
PEG Ratio | 3.52 | |||||
PS Ratio | 3.01 | |||||
PB Ratio | 4.69 | |||||
Price-to-Free-Cash-Flow | 10.47 | |||||
Price-to-Operating-Cash-Flow | 9.75 | |||||
EV-to-EBIT | 50.3 | |||||
EV-to-Forward-EBIT | 10.3 | |||||
EV-to-EBITDA | 21.46 | |||||
EV-to-Forward-EBITDA | 8.81 | |||||
EV-to-Revenue | 3.74 | |||||
EV-to-Forward-Revenue | 4.15 | |||||
EV-to-FCF | 12.99 | |||||
Price-to-Projected-FCF | 0.86 | |||||
Price-to-Median-PS-Value | 0.81 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.25 | |||||
Earnings Yield (Greenblatt) % | 1.99 | |||||
FCF Yield % | 9.61 | |||||
Forward Rate of Return (Yacktman) % | 18.47 |